Ucb Pharma Gmbh

Schwarz Pharma Ag

Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh

Apr Applied Pharma Research Sa

Labtec Gesellschaft Fuer Technologische Forschung Und Entwicklung Mbh

Lab International Barbados, Srl

Armin Breitenbach

Hans-Michael Wolff

Claus Meese

Roland Drews

Thomas Kissel

Ingo Lehrke

Paolo Galfetti

Christian Leichs

Walter Kamm

Tobias Jung

The invention relates to a transdermal therapeutic system (TTS) which contains a rotigotine-containing adhesive layer and is characterized by the fact that the adhesive layer contains a hot-meltable contact adhesive. The invention also relates to the use of rotigotine for producing the adhesive layer of a TTS in a hot melt method, and a method for producing such a TTS.

Hot melt TTS for administering rotigotine

The invention relates to a polymer matrix suitable for the transdermal administration of rotigotine [(&#x2212;)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphtol], containing a matrix for the transdermal administration of rotigotine [(&#x2212;)-5, 6, 7, 8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1 naphtol], containing a matrix polymer which is supersaturated with a rotigotine base. Said polymer matrix is characterised in that the part of the rotigotine which is not dissolved in the matrix polymer is dispersed in the matrix polymer as amorphous particles having a maximum mean diameter of 30 &#x3bc;m, and the matrix is free of solubilisers, crystallisation inhibitors and dispersants. The invention also relates to a flat device for the transdermal administration of rotigotine, containing the above-mentioned, preferably silicon-based polymer matrix which is supersaturated with rotigotine, and a rear layer which is impermeable to the active ingredient.

Device for the transdermal administration of a rotigotine base

This patent application relates to a transdermal therapeutic system (TTS) that comprises a Rotigotine-containing cement layer, characterized in that the cement layer contains a hot-meltable adhesive in which Rotigotine as the active substance is dispersed and partly or completely dissolved. The patent application further relates to the use of Rotigotine in the production of the cement layer of a TTS by a hot-melt method.

Hot-melt TTS for administering rotigotine

The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from Calkyl, Ccycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterized in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments. 

High purity bases of 3,3-diphenylpropylamino monoesters

The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among Calkyl, Ccycloalkyl, or phenyl, each of which can be substituted by Calkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments. 

Transdermal delivery of (R)-3,3-diphenylpropylamin-monoestern

Transdermal administration of (R)-3,3-diphenylpropylamin-monoesters

The invention is directed to self-assembling, polymer-based delivery systems for proteins. The delivery systems comprises an active agent and a polyol ester of the invention, having a linear polyol containing six or more hydroxyl groups as a central backbone and biodegradable hydroxy carboxylic ester groups attached to the central backbone.

Growing community of inventors

Monheim, Germany

Armin Breitenbach